NEXTERA ENERGY INC

**Signal Note: Eventide's NEE-PV Entry Misaligned with Biotech Focus** Eventide's $8.1M initiation in NextEra Energy's preferred shares represents a notable departure from their stated biotech-concentrated strategy, suggesting either portfolio diversification into clean energy infrastructure or tactical capital deployment outside core holdings. The move lacks typical biotech catalysts (clinical data, regulatory milestones, or pipeline advancement) and instead reflects a fixed-income/yield positioning, which warrants clarification on whether this signals reduced conviction in near-term biotech valuations or represents a separately-managed allocation.